Omega 3 Platinum + D 2000 mg
Product analysis
Omega 3 Platinum + D 2000 mg offers omega-3 fats for triglyceride-related support. Incomplete identification and amount details make parts of the formula harder to compare.
AI assessment of the formula, label and price. How scoring works
Nutrient Quality27
The mixed ingredient is not clearly identified, leaving its quality uncertain. The other components also lack specific form details, limiting a confident preparation comparison.
Ingredient Transparency51
Some amounts and form details are stated, but the mixed ingredient lacks a clear identity and amount. Its composition remains uncertain, limiting comparison of the full serving.
Value For Money40
Value for the active content remains uncertain. There is not enough information for a confident comparison of cost and contribution.
Customer Satisfaction77
Customer ratings indicate strong satisfaction. A few hundred ratings provide some breadth of feedback, though the pool remains moderate.
Product Focus72
The clearest role involves omega-3 support for triglyceride-related markers. Joint-comfort findings are mixed, and adding vitamin D does not establish extra cardiovascular protection.
- Format
Softgel - Container
- 90 Softgel(s)
- Per serving
- $0.67
- Customer rating
- 4.8 · 328 ratings
Goals
EPA and DHA contribute to fatty-acid signals involved in inflammation, with human studies reporting reductions in inflammation markers but inconsistent results across settings. The serving declares EPA and DHA separately; fish-oil mass is not the active omega-3 amount. Vitamin D has shown a temporary reduction in one inflammation marker in older adults, while other markers and longer follow-up were unchanged. Routine anti-inflammatory clinical benefit remains unestablished.
How this product is rated for Inflammation
Ingredient fit74
Goal fit
Dose adequacy
Pathways60
Depth
Breadth
Evidence93
Evidence strength
Studied preparation
Formulation logic100
Partner coverage
Conflicts
Effective doses
EPA and DHA provide the main connection through triglyceride metabolism. Their declared active amounts contribute separately; total oil weight does not establish the same exposure. Supporting studies concern blood markers in specific populations and do not establish prevention of cardiovascular events.
How this product is rated for Cardiovascular Support
Ingredient fit84
Goal fit
Dose adequacy
Pathways60
Depth
Breadth
Evidence83
Evidence strength
Studied preparation
Formulation logic100
Partner coverage
Conflicts
Effective doses
EPA has limited support for triglyceride-related effects, distinct from prevention of major cardiovascular events. An active-catalogue DHA declaration is present, while the separate linked DHA identity remains unresolved and was not credited in the saved findings. Vitamin D does not establish cardiovascular prevention from this serving. Fish-oil mass and the combination do not add independent benefit.
How this product is rated for Heart Health
Ingredient fit82
Goal fit
Dose adequacy
Pathways44
Depth
Breadth
Evidence100
Evidence strength
Studied preparation
Formulation logic100
Partner coverage
Conflicts
Effective doses
Omega-3 studies found differing resting-metabolic-rate effects in older women and young men, so a general increase cannot be assumed. The supplied findings do not establish a sustained rise in metabolic rate or weight loss from this serving.
How this product is rated for Metabolism Support
Ingredient fit65
Goal fit
Dose adequacy
Pathways20
Depth
Breadth
Evidence89
Evidence strength
Studied preparation
Formulation logic100
Partner coverage
Conflicts
Effective doses
Omega-3 fatty acids, including EPA and DHA, may provide small improvements in joint pain, stiffness or function in some inflammatory-joint and osteoarthritis settings. Findings are mixed, with important large trials showing no benefit. The evidence concerns sustained study regimens, so a label serving does not establish the same exposure or outcome, and it does not show cartilage repair or prevention. Vitamin D receives a saved contribution, but the supplied OA trial does not establish knee-pain or cartilage-volume benefit.
How this product is rated for Joint Health
Ingredient fit78
Goal fit
Dose adequacy
Pathways18
Depth
Breadth
Evidence69
Evidence strength
Studied preparation
Formulation logic100
Partner coverage
Conflicts
Effective doses
DHA and EPA are relevant to longer-term brain nutrition, but the supplied cognitive findings concern repeated intake and selected populations. Those findings do not establish an immediate improvement in focus from this serving, and fish-oil quantity cannot substitute for the separately declared fatty acids.
How this product is rated for Mental Focus
Ingredient fit74
Goal fit
Dose adequacy
Pathways50
Depth
Breadth
Evidence64
Evidence strength
Studied preparation
Formulation logic100
Partner coverage
Conflicts
Effective doses
No linked studies yet.
Omega-3 has some human evidence involving responses to UV exposure, but it concerns a specific purified EPA preparation. That evidence does not establish equivalent skin benefits from this product’s generic omega-3 or total oil amounts. Although the saved findings emphasize the skin barrier, routine improvements in hydration or barrier function cannot be inferred for this preparation.
How this product is rated for Skin Health
Ingredient fit78
Goal fit
Dose adequacy
Pathways50
Depth
Breadth
Evidence78
Evidence strength
Studied preparation
Formulation logic100
Partner coverage
Conflicts
Effective doses
Ingredients
| Ingredient | Amount per serving | Score |
|---|---|---|
Calories | 20 Calorie(s) | |
Total Fat | 2 Gram(s) | |
Vitamin D3 (Cholecalciferol) | 50 mcg | |
Fish Oil | 2000 mg | |
EPA (TG) | 600 mg | |
DHA (TG) | 400 mg | |
Total Omega-3 (Triglycerides) | 1100 mg |
How this ingredient is rated
Active Ingredient Quality & Bioavailability72
Molecular Form & Absorption Potential
Source Purity & Oxidative Protection
Dose, Safety & Label Transparency55
EPA & DHA Label Specificity
Active Ingredient Concentration
Third-Party Purity Verification
Value80
Price per 1000mg of EPA+DHA
How this ingredient is rated
Active Ingredient Quality & Bioavailability65
Molecular Form and Bioavailability
EPA Concentration Density
Oxidation Protection
Dose, Safety & Label Transparency70
Absolute EPA Dose per Serving
EPA-Centric Ratio
Purity and Contaminant Testing
Value50
Price per Gram of EPA
How this ingredient is rated
Active Ingredient Quality & Bioavailability44
Omega-3 Molecular Form
Purification & Filtration Method
Third-Party Purity & Potency Verification
Source & Sustainability
Dose, Safety & Label Transparency69
Total Active Omega-3 Dose (EPA + DHA)
Omega-3 Potency & Concentration
EPA & DHA Individual Disclosure
Oxidation Protection (Stabilizers)
Value50
Cost Per Gram of Active EPA + DHA
Alternative products
Sources
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
- Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials Involving 127 477 Participants.
- Impact of omega-3 fatty acids on hypertriglyceridemia, lipidomics, and gut microbiome in patients with type 2 diabetes.
- A systematic review of fish-oil supplements for the prevention and treatment of hypertension.
- Effects of fish oil-derived fatty acids on suboptimal cardiovascular health: A multicenter, randomized, double-blind, placebo-controlled trial.
- Effect of High-Dose Marine Omega-3 Fatty Acids on Atherosclerosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
- Comparative Efficacy of Nutraceuticals on Endothelial Function: A Systematic Review and Network Meta-Analysis.
- A Randomized Trial of Vitamin D Supplementation on Vascular Function in CKD.
- Randomized, placebo-controlled, double-blind clinical trial on the contributions of vitamin D in the control of cardiovascular risk factors, depressive symptoms and suicide risk.
- Dose responses of vitamin D3 supplementation on arterial stiffness in overweight African Americans with vitamin D deficiency: A placebo controlled randomized trial.
- Paricalcitol and endothelial function in chronic kidney disease trial.
- Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.
- Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS).
- Effects of omega-3 fatty acids on coronary revascularization and cardiovascular events: a meta-analysis.
- Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease.
- Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association.
- Vitamin D supplementation for cardiometabolic risk markers in pregnant women based on the gestational diabetes mellitus or obesity status : a randomized clinical trial.
- Vitamin D Supplementation, Serum 25(OH)D Concentrations and Cardiovascular Disease Risk Factors: A Systematic Review and Meta-Analysis.
- Does vitamin D supplementation modulate metabolic risk factors of cardiovascular disease? A systematic review and meta-analysis of clinical trials.
- Dose-dependent effects of fish oil on cardio-metabolic biomarkers in healthy middle-aged and elderly Chinese people: a double-blind randomized controlled trial.
- Eicosapentaenoic acid supplementation alleviates pruritus, enhances skin moisture, and mitigates depression in maintenance hemodialysis patients.